Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
BIOLASE reported strong financial results for Q2 2022, with total revenue of $12.2 million, up 34% year-over-year. U.S. laser sales surged 70% and consumable sales rose 42%. The company noted significant growth in new customers, with 80% of U.S. Waterlase sales attributed to them. However, the gross margin decreased to 42% from 44%, partly due to supply chain challenges. The net loss was $5.6 million, compared to a loss of $0.7 million in Q2 2021. Looking ahead, BIOLASE expects third quarter revenue to exceed $10.5 million, indicating at least 10% year-over-year growth.
BIOLASE, the leader in dental lasers, will release its second quarter 2022 financial results on August 11, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss these results and corporate developments. Investors can participate by calling 877-545-0320 (U.S.) or +1 973-528-0002 (International) with the earnings code: 838343. The call will be accessible via a live and archived webcast on the BIOLASE Investor Relations Page. BIOLASE focuses on developing innovative dental laser systems for improved patient outcomes.
BIOLASE (NASDAQ: BIOL) strengthens its position in the dental laser industry with the acquisition of five new U.S. patents and seven foreign patents in the past year, maintaining a total of 302 issued and 31 pending patents.
Significant additions include a patent for Pre-Initiated Optical Fibers for Medical Applications from Korea and a Dual Wavelength Laser Treatment Device from Canada. The company’s innovative laser products are designed for superior clinical performance and patient comfort, ensuring long-term protection of its intellectual property.
BIOLASE, Inc. (NASDAQ: BIOL) has initiated a pilot program with Einstein Healthcare Network to train General Dentistry residents in utilizing Waterlase dental laser technology. This program aims to equip future dentists with hands-on experience in laser-assisted dentistry, integral for modern practices. The collaboration emphasizes BIOLASE's commitment to advancing dental education, enhancing patient experiences, and fostering efficient practices. Einstein's General Dentistry residency, recognized by the American Dental Association, supports this initiative as part of its curriculum to prepare residents for effective general dental practice.
BIOLASE, Inc. (NASDAQ: BIOL) announced the immediate appointments of Jennifer Bright as Chief Financial Officer and Steven Sandor as Chief Operating Officer, both reporting to President John Beaver. Bright, previously Vice President of Finance, aims to drive financial strategy and investor relations, leveraging her extensive experience in corporate finance. Sandor, who joined in 2019, focuses on improving processes and driving results across sales, marketing, and service sectors. These leadership changes are expected to enhance collaboration and market focus, particularly on the Dental Service Organization sector.
BIOLASE, Inc. (NASDAQ: BIOL) announced a partnership with TeamSmile to provide free dental care to children using Waterlase technology. This initiative aims to deliver pain-free, minimally invasive dental treatments at TeamSmile events across the U.S. Since its inception, TeamSmile has treated over 45,000 children and provided over $18 million in dental care. BIOLASE's iPlus Waterlase laser systems will enhance the quality of care offered, allowing for cavity removals without the need for drills or anesthetics. This partnership highlights BIOLASE's commitment to improving oral health in underserved communities.
On June 30, 2022, BIOLASE entered into an amendment to its senior secured term loan with SWK Funding LLC, extending the interest-only period by two quarters to November 2023. The amendment also reduces the minimum Consolidated Unencumbered Liquid Assets from $7.5 million to $5.5 million. Using proceeds from a recent equity offering, BIOLASE prepaid $1 million of the loan balance, aiming to lower interest expenses and enhance liquidity. This partnership with SWK supports BIOLASE's mission to advance dental laser technology.
BIOLASE, a leader in dental lasers, has entered into a securities purchase agreement with an institutional investor to raise $6.5 million through a registered direct offering and concurrent private placement. The transaction involves the sale of 1,405,405 shares of common stock and warrants priced at $4.625 each. The offering is anticipated to close by June 30, 2022, pending customary closing conditions. Maxim Group LLC is the lead placement agent. The shares are offered under an effective shelf registration statement with the SEC.
BIOLASE (NASDAQ: BIOL) has partnered with Project HOME, a Philadelphia-based organization dedicated to providing dental and healthcare services to individuals in need, regardless of their ability to pay. As part of this collaboration, BIOLASE donated an iPlus Waterlase laser system and will offer training to Project HOME staff. This initiative aims to enhance the quality of dental care provided and improve health outcomes for underserved populations. BIOLASE's commitment underscores its mission to deliver advanced dental laser technology and contribute positively to community health.
BIOLASE (NASDAQ: BIOL) has extended its digital learning webinar series, Advancing Dentistry, through Q3 2022. The series aims to provide remote training and CE credits for dental professionals, featuring key opinion leaders sharing insights on laser integration in practice. Events will take place from July to August 2022, covering various dental specialties. These webinars are designed to promote the adoption of laser technology, enhancing patient care. This initiative highlights BIOLASE's commitment to education and innovation in the dental field.